Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:IPHA NASDAQ:LTRN NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.22+2.6%$5.45$4.31▼$9.56$171.24M1.09207,665 shs125,517 shsIPHAInnate Pharma$1.79+1.7%$1.57$1.17▼$2.63$168.12M0.3148,401 shs8,171 shsLTRNLantern Pharma$3.84+13.0%$2.47$1.11▼$5.74$43.45M2.33419,497 shs338,346 shsNRXPNRx Pharmaceuticals$4.05$2.94$1.62▼$5.05$146.73M2.141.18 million shs1.40 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+0.66%+1.17%+16.76%-22.80%-15.83%IPHAInnate Pharma-3.30%+0.57%+22.22%+11.39%-17.76%LTRNLantern Pharma-9.09%+2.72%+60.38%+24.54%+5.59%NRXPNRx Pharmaceuticals-12.01%-5.37%+31.07%+128.81%+48.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.22+2.6%$5.45$4.31▼$9.56$171.24M1.09207,665 shs125,517 shsIPHAInnate Pharma$1.79+1.7%$1.57$1.17▼$2.63$168.12M0.3148,401 shs8,171 shsLTRNLantern Pharma$3.84+13.0%$2.47$1.11▼$5.74$43.45M2.33419,497 shs338,346 shsNRXPNRx Pharmaceuticals$4.05$2.94$1.62▼$5.05$146.73M2.141.18 million shs1.40 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+0.66%+1.17%+16.76%-22.80%-15.83%IPHAInnate Pharma-3.30%+0.57%+22.22%+11.39%-17.76%LTRNLantern Pharma-9.09%+2.72%+60.38%+24.54%+5.59%NRXPNRx Pharmaceuticals-12.01%-5.37%+31.07%+128.81%+48.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.25Hold$13.00109.00% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00179.33% UpsideLTRNLantern Pharma 1.00SellN/AN/ANRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25844.44% UpsideCurrent Analyst Ratings BreakdownLatest LTRN, DERM, NRXP, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/7/2026LTRNLantern Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.004/27/2026NRXPNRx Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $49.004/27/2026NRXPNRx Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.004/21/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026DERMJourney Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$61.86M2.77N/AN/A$0.96 per share6.48IPHAInnate Pharma$10.19M16.50N/AN/A($0.26) per share-6.88LTRNLantern PharmaN/AN/AN/AN/A$0.58 per shareN/ANRXPNRx Pharmaceuticals$1.23M119.29N/AN/A($0.54) per share-7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$11.43M-$0.37N/A4.29N/A-14.82%-35.57%-10.88%8/11/2026 (Estimated)IPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/ALTRNLantern Pharma-$17.12M-$1.45N/AN/AN/AN/A-198.34%-129.08%8/12/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.86N/AN/AN/A-202.92%8/17/2026 (Estimated)Latest LTRN, DERM, NRXP, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026LTRNLantern Pharma-$0.36-$0.30+$0.06-$0.30N/AN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/13/2026Q1 2026DERMJourney Medical-$0.07-$0.08-$0.01-$0.08$15.47 million$15.96 million3/30/2026Q4 2025LTRNLantern Pharma-$0.46-$0.36+$0.10-$0.36N/AN/A3/25/2026Q4 2025DERMJourney Medical-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 million3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.20$7.53 million$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical0.741.721.47IPHAInnate PharmaN/A1.271.27LTRNLantern PharmaN/A1.871.87NRXPNRx PharmaceuticalsN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%IPHAInnate Pharma0.16%LTRNLantern Pharma28.62%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%IPHAInnate Pharma31.89%LTRNLantern Pharma8.50%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9027.53 million23.40 millionN/AIPHAInnate Pharma22093.92 million63.97 millionNot OptionableLTRNLantern Pharma2011.31 million10.34 millionOptionableNRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableLTRN, DERM, NRXP, and IPHA HeadlinesRecent News About These CompaniesNRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics10 minutes ago | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' Option29 minutes ago | globenewswire.comNRx Pharmaceuticals Plans Underwritten Public Stock OfferingJune 4 at 2:48 AM | theglobeandmail.comNRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 MillionJune 3 at 8:30 AM | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockJune 3 at 8:18 AM | globenewswire.comNRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's whyJune 3 at 6:43 AM | msn.comNRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockJune 2 at 4:01 PM | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 1 at 2:16 AM | americanbankingnews.comQ2 EPS Forecast for NRx Pharmaceuticals Decreased by AnalystJune 1 at 1:01 AM | marketbeat.comNRx Pharmaceuticals (Nasdaq: NRXP) Strategic Partner Emobot Presents Late-Breaking Clinical Validation of the EMOCARE Depression Thermometer at ASCP 2026May 28, 2026 | globenewswire.comNRx (NRXP) Q1 2026 Earnings Call TranscriptMay 27, 2026 | fool.comNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemMay 27, 2026 | globenewswire.comHere is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24, 2026 | insidermonkey.comNRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market UncertaintyMay 20, 2026 | seekingalpha.comNRx Pharmaceuticals Q1 Earnings Call HighlightsMay 18, 2026 | marketbeat.comNRx Pharmaceuticals Reports Q1 2026 Milestones, Including Advancements in Ketamine and NRX-101 DevelopmentMay 18, 2026 | quiverquant.comQNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 18, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2026 | zacks.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateMay 14, 2026 | globenewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in ...May 7, 2026 | markets.businessinsider.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and SuicidalityMay 7, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLTRN, DERM, NRXP, and IPHA Company DescriptionsJourney Medical NASDAQ:DERM$6.22 +0.16 (+2.64%) Closing price 04:00 PM EasternExtended Trading$6.23 +0.01 (+0.16%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Innate Pharma NASDAQ:IPHA$1.79 +0.03 (+1.70%) Closing price 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Lantern Pharma NASDAQ:LTRN$3.84 +0.44 (+13.00%) Closing price 03:59 PM EasternExtended Trading$3.82 -0.03 (-0.70%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.NRx Pharmaceuticals NASDAQ:NRXP$4.05 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$4.01 -0.04 (-0.86%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
